Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Patrick Balthrop, John Coulter, Rohan Hastie, Robert Greczyn, and More

Premium

AdvaMedDx has elected new members to its board of directors, including Luminex CEO Patrick Balthrop; John Coulter, VP of molecular diagnostics at Abbott Laboratories; Rohan Hastie, general manager of diagnostics at Hologic; and Robert Greczyn, interim president and CEO of LipoScience.


Transgenomic announced that Paul Kinnon has been named president, CEO, and a director of the company, replacing Craig Tuttle. Kinnon joins Transgenomic from New Zealand-based ZyGem, where he served as president and CEO. Kinnon joined ZyGem in 2007 from Invitrogen, where he held the positions of vice president of global strategic alliances and vice president and general manager of the applied markets business unit. Prior to that, Kinnon held business, sales, and marketing roles at Guava Technologies (now part of Millipore), Cellomics (now part of Thermo Fisher Scientific), and other life science companies.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.